Nogueira Guerra Leonor, Herdeiro Maria Teresa, Ribeiro-Vaz Inês, Clérigo Maria Inês Pinto, Rocha Cristina, Araújo Ana, Pêgo Alexandra, Rebelo Gomes Eva
a Direção de Gestão do Risco de Medicamentos, Infarmed - Autoridade Nacional do Medicamento e Produtos de Saúde , I.P. , Lisboa, Portugal.
b Institute for Research in Biomedicine - iBiMED & Health Sciences Department, Aveiro, Portugal CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde , Gandra , Portugal.
Expert Opin Drug Saf. 2015;14(12):1805-13. doi: 10.1517/14740338.2015.1105214. Epub 2015 Nov 7.
Adverse drug reactions (ADR) are a public health problem. They cause significant morbidity, mortality and health costs. Less is known about pediatric ADR. Our goal was to characterize a pediatric case series of ADR reported to the Portuguese Pharmacovigilance System (PPS) during the past 10 years.
Retrospective analysis of ADR reports concerning patients till 17 years old received by the PPS between 2003 and 2012. We evaluated patients' demographic data and involved drugs, as well as characteristics and seriousness of reactions, stratified by age groups.
We found 1742 reports (50% females) corresponding to 9.7% of the total received. The age of the patients varied from 0 to 17 years (median: 5 years, interquartile range: 10.6), with 566 cases (32%) occurring in patients younger than 2y. Among the 1195 serious cases, 31% (370) episodes led to hospitalization. In 32 cases (2%) there was a fatal outcome. Most of the ADR reported referred to general disorders and administration site conditions, followed by skin and subcutaneous tissue reactions. Vaccines were the most represented group (42%) followed by antibacterials for systemic use (17%).
Pediatric ADR represents about 10% of the reports received by the PPS. Most ADR were considered serious. Major findings varied according to age groups.
药物不良反应(ADR)是一个公共卫生问题。它们会导致严重的发病率、死亡率和医疗成本。关于儿科ADR的了解较少。我们的目标是对过去10年向葡萄牙药物警戒系统(PPS)报告的儿科ADR病例系列进行特征描述。
对PPS在2003年至2012年期间收到的有关17岁及以下患者的ADR报告进行回顾性分析。我们评估了患者的人口统计学数据、所涉及的药物,以及反应的特征和严重程度,并按年龄组进行分层。
我们发现了1742份报告(50%为女性),占总收到报告的9.7%。患者年龄从0岁到17岁不等(中位数:5岁,四分位间距:10.6),其中566例(32%)发生在2岁以下的患者中。在1195例严重病例中,31%(370例)导致住院。32例(2%)出现了致命结果。报告的大多数ADR涉及全身疾病和给药部位情况,其次是皮肤和皮下组织反应。疫苗是最主要的类别(42%),其次是全身用抗菌药物(17%)。
儿科ADR约占PPS收到报告的10%。大多数ADR被认为是严重的。主要发现因年龄组而异。